Intraductal Papillary Mucinous Neoplasm of the Pancreas

Zhi Ven Fong; Carlos Fernández-Del Castillo

doi:10.1016/j.suc.2016.07.009

Intraductal Papillary Mucinous Neoplasm of the Pancreas

Surg Clin North Am. 2016 Dec;96(6):1431-1445. doi: 10.1016/j.suc.2016.07.009.

Authors

Zhi Ven Fong¹, Carlos Fernández-Del Castillo²

Affiliations

¹ Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114-3117, USA.
² Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114-3117, USA. Electronic address: cfernandez@partners.org.

PMID: 27865286
DOI: 10.1016/j.suc.2016.07.009

Abstract

The incidence of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas has been rising in the past 2 decades, driven mainly by the widespread use of cross-sectional imaging. IPMNs are intraductal mucin-producing neoplasms that involve the main pancreatic duct or its side branches and lack the ovarian stroma typically seen in mucinous cystic neoplasms. The International Association of Pancreatology released consensus guidelines in 2006 and 2012 providing clinical algorithms based on IPMN features and risk of malignancy. In this article, we review the different classifications of IPMNs, their natural history, and clinical management and address recent controversies in the literature.

Keywords: Biology; Clinical management; Intraductal papillary mucinous neoplasm; Pancreas.

Publication types

Review

MeSH terms

Carcinoma, Pancreatic Ductal* / diagnosis
Carcinoma, Pancreatic Ductal* / epidemiology
Carcinoma, Pancreatic Ductal* / therapy
Carcinoma, Papillary* / diagnosis
Carcinoma, Papillary* / epidemiology
Carcinoma, Papillary* / therapy
Combined Modality Therapy
Humans
Neoplasm Staging*
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / epidemiology
Pancreatic Neoplasms* / therapy